BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 22954303)

  • 1. miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer.
    Nordentoft I; Birkenkamp-Demtroder K; Agerbæk M; Theodorescu D; Ostenfeld MS; Hartmann A; Borre M; Ørntoft TF; Dyrskjøt L
    BMC Med Genomics; 2012 Sep; 5():40. PubMed ID: 22954303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circular RNA Cdr1as sensitizes bladder cancer to cisplatin by upregulating APAF1 expression through miR-1270 inhibition.
    Yuan W; Zhou R; Wang J; Han J; Yang X; Yu H; Lu H; Zhang X; Li P; Tao J; Wei J; Lu Q; Yang H; Gu M
    Mol Oncol; 2019 Jul; 13(7):1559-1576. PubMed ID: 31131537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiR-486-5p enhances cisplatin sensitivity of human muscle-invasive bladder cancer cells by induction of apoptosis and down-regulation of metastatic genes.
    Salimian J; Baradaran B; Azimzadeh Jamalkandi S; Moridikia A; Ahmadi A
    Urol Oncol; 2020 Sep; 38(9):738.e9-738.e21. PubMed ID: 32527702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. rs11671784 G/A variation in miR-27a decreases chemo-sensitivity of bladder cancer by decreasing miR-27a and increasing the target RUNX-1 expression.
    Deng Y; Bai H; Hu H
    Biochem Biophys Res Commun; 2015 Mar; 458(2):321-7. PubMed ID: 25656571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIF-1α-dependent miR-424 induction confers cisplatin resistance on bladder cancer cells through down-regulation of pro-apoptotic UNC5B and SIRT4.
    Yu M; Ozaki T; Sun D; Xing H; Wei B; An J; Yang J; Gao Y; Liu S; Kong C; Zhu Y
    J Exp Clin Cancer Res; 2020 Jun; 39(1):108. PubMed ID: 32522234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-199a-3p and miR-214-3p improve the overall survival prediction of muscle-invasive bladder cancer patients after radical cystectomy.
    Ecke TH; Stier K; Weickmann S; Zhao Z; Buckendahl L; Stephan C; Kilic E; Jung K
    Cancer Med; 2017 Oct; 6(10):2252-2262. PubMed ID: 28879675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased expression of transcription factor TFAP2α correlates with chemosensitivity in advanced bladder cancer.
    Nordentoft I; Dyrskjøt L; Bødker JS; Wild PJ; Hartmann A; Bertz S; Lehmann J; Orntoft TF; Birkenkamp-Demtroder K
    BMC Cancer; 2011 Apr; 11():135. PubMed ID: 21489314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogene miR-187-5p is associated with cellular proliferation, migration, invasion, apoptosis and an increased risk of recurrence in bladder cancer.
    Li Z; Lin C; Zhao L; Zhou L; Pan X; Quan J; Peng X; Li W; Li H; Xu J; Xu W; Guan X; Chen Y; Lai Y
    Biomed Pharmacother; 2018 Sep; 105():461-469. PubMed ID: 29883941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of miRNAs involved in angiogenesis, tumor cell proliferation, tumor suppressor inhibition, epithelial-mesenchymal transition and activation of metastasis in bladder cancer.
    Zaravinos A; Radojicic J; Lambrou GI; Volanis D; Delakas D; Stathopoulos EN; Spandidos DA
    J Urol; 2012 Aug; 188(2):615-23. PubMed ID: 22704449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-203 Is a Prognostic Indicator in Bladder Cancer and Enhances Chemosensitivity to Cisplatin via Apoptosis by Targeting Bcl-w and Survivin.
    Zhang X; Zhang Y; Liu X; Fang A; Li P; Li Z; Liu T; Yang Y; Du L; Wang C
    PLoS One; 2015; 10(11):e0143441. PubMed ID: 26599571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST.
    Zhou Y; Huang Z; Wu S; Zang X; Liu M; Shi J
    J Exp Clin Cancer Res; 2014 Jan; 33(1):12. PubMed ID: 24468065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA damage responsive miR-33b-3p promoted lung cancer cells survival and cisplatin resistance by targeting p21
    Xu S; Huang H; Chen YN; Deng YT; Zhang B; Xiong XD; Yuan Y; Zhu Y; Huang H; Xie L; Liu X
    Cell Cycle; 2016 Nov; 15(21):2920-2930. PubMed ID: 27559850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-325 Is a Potential Biomarker and Tumor Regulator in Human Bladder Cancer.
    Lin T; Zhou S; Gao H; Li Y; Sun L
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818790536. PubMed ID: 30176759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-142-5p enhances cisplatin-induced apoptosis in ovarian cancer cells by targeting multiple anti-apoptotic genes.
    Li X; Chen W; Jin Y; Xue R; Su J; Mu Z; Li J; Jiang S
    Biochem Pharmacol; 2019 Mar; 161():98-112. PubMed ID: 30639456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EHHADH contributes to cisplatin resistance through regulation by tumor-suppressive microRNAs in bladder cancer.
    Okamura S; Yoshino H; Kuroshima K; Tsuruda M; Osako Y; Sakaguchi T; Yonemori M; Yamada Y; Tatarano S; Nakagawa M; Enokida H
    BMC Cancer; 2021 Jan; 21(1):48. PubMed ID: 33430801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin and Paclitaxel Alter the Expression Pattern of miR-143/145 and miR-183/96/182 Clusters in T24 Bladder Cancer Cells.
    Papadopoulos EI; Scorilas A
    Clin Transl Sci; 2015 Dec; 8(6):668-75. PubMed ID: 26356996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.
    van Jaarsveld MT; Helleman J; Boersma AW; van Kuijk PF; van Ijcken WF; Despierre E; Vergote I; Mathijssen RH; Berns EM; Verweij J; Pothof J; Wiemer EA
    Oncogene; 2013 Sep; 32(36):4284-93. PubMed ID: 23045278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome.
    Ratert N; Meyer HA; Jung M; Lioudmer P; Mollenkopf HJ; Wagner I; Miller K; Kilic E; Erbersdobler A; Weikert S; Jung K
    J Mol Diagn; 2013 Sep; 15(5):695-705. PubMed ID: 23945108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11.
    Drayton RM; Dudziec E; Peter S; Bertz S; Hartmann A; Bryant HE; Catto JW
    Clin Cancer Res; 2014 Apr; 20(7):1990-2000. PubMed ID: 24516043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA expression and clinical outcome of small cell lung cancer.
    Lee JH; Voortman J; Dingemans AM; Voeller DM; Pham T; Wang Y; Giaccone G
    PLoS One; 2011; 6(6):e21300. PubMed ID: 21731696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.